Skip to main content
SpringerLink
Log in
Book cover

Annual Update in Intensive Care and Emergency Medicine 2015 pp 85–90Cite as

Optimizing Antimicrobial Efficacy at Minimal Toxicity: A Novel Indication for Continuous Renal Replacement Therapy?

  • Chapter

  • 2528 Accesses

Part of the book series: Annual Update in Intensive Care and Emergency Medicine 2015 ((AUICEM,volume 2015))

Abstract

Continuous renal replacement therapy (CRRT) has become a standard adjuvant therapy in the intensive care unit (ICU). Apart from commonly accepted indications, such as acute kidney injury (AKI) of different origins, hemodynamic instability without AKI and fluid overload, CRRT can act as a ‘supportive’ therapy that allows adequate dosing of antimicrobials whilst limiting some or all of their known toxicities. In particular, CRRT may elegantly reconcile optimal treatment efficacy and safety when high doses of antimicrobial agents have to be administered for an extended time period [1, 2]. In this chapter, we briefly review the literature and share our own experience regarding some antibiotics and antifungals when this ‘novel’ CRRT approach is realized.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Honoré PM, Jacobs R, Joannes-Boyau O et al (2014) Continuous renal replacement therapy-related strategies to avoid colistin toxicity: A clinically orientated review. Blood Purif 37:291–295

    Article  PubMed  Google Scholar 

  2. Honore PM, Jacobs R, Joannes-Boyau O et al (2013) Continuous renal replacement therapy allows higher colistin dosing without increasing toxicity. J Transl Intern Med 1:6–8

    Article  Google Scholar 

  3. Li J, Nation RL, Turnidge JD et al (2006) Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589–601

    Article  CAS  PubMed  Google Scholar 

  4. Mohamed AF, Karaiskos I, Plachouras D et al (2012) Application of a loading dose of colistin methanesulfonate in critically ill patients: Population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:4241–4249

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Marchand S, Frat JP, Petitpas F et al (2010) Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 65:1836–1837

    Article  CAS  PubMed  Google Scholar 

  6. Markou N, Fousteri M, Markantonis SL et al (2012) Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: Anobservational study. J Antimicrob Chemother 67:2459–2462

    Article  CAS  PubMed  Google Scholar 

  7. Cho YS, Yim H, Yang HT et al (2012) Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea. Infection 40:27–33

    Article  CAS  PubMed  Google Scholar 

  8. Li J, Rayner CR, Nation RL et al (2005) Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 49:4814–4815

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Plachouras D, Karvanen M, Friberg LE et al (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:3430–3436

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Honore PM, Jacobs R, Lochy S et al (2013) Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: Key potential role of hemoadsorption elimination during continuous venovenous hemofiltration. Int J Nephrol Renovasc Dis 6:107–111

    Article  PubMed Central  PubMed  Google Scholar 

  11. Lee J, Han S, Jeon S et al (2013) Population pharmacokinetic analysis of colistin in burn patients. Antimicrob Agents Chemother 57:2141–2146

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Honore PM, Jacobs R, Joannes-Boyau O et al (2013) Newly designed CRRT membranes for sepsis and SIRS – a pragmatic approach for bedside intensivists summarizing the more recent advances: A systematic structured review. ASAIO J 59:99–106

    Article  CAS  PubMed  Google Scholar 

  13. Morimatsu H, Uchino S, Bellomo R, Ronco C (2003) Continuous renal replacement therapy: Does technique influence electrolyte and bicarbonate control? Int J Artif Organs 4:289–296

    Google Scholar 

  14. Kellum JA, Lameire N (2013) Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Crit Care 17:R204

    Google Scholar 

  15. Joannes-Boyau O, Honoré PM, Perez P et al (2013) High-volume versus standard-volume haemofiltration forseptic shock patients with acute kidney injury (IVOIRE study):A multicentre randomized controlled trial. Intensive Care Med 39:1535–1546

    Article  PubMed  Google Scholar 

  16. Zhang P, Yang Y, Lv R et al (2012) Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: A single-center randomized clinical trial. Nephrol Dial Transplant 27:967–973

    Article  CAS  PubMed  Google Scholar 

  17. Spapen HD, Honore PM, Gregoire N et al (2011) Convulsions and apnoea in a patient infected with New Delhi metallo-β-lactamase-1 Escherichia coli treated with colistin. J Infect 63:468–470

    Article  PubMed  Google Scholar 

  18. Honore PM, Joannes-Boyau O, Collin V, Boer W, Gressens B, Janvier G (2008) Practical daily management of extra-renal continuous removal. Reanimation 17:472–478

    Article  Google Scholar 

  19. Tian Q, Gomersall CD, Ip M, Joynt GM (2011) Effect of preexposure to aminoglycosides on in vitro adsorption of amikacin by polyacrylonitrile hemofilters. Antimicrob Agents Chemother 55:3641–3642

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Hofbauer R, Moser D, Frass M et al (1999) Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 56:1578–1583

    Article  CAS  PubMed  Google Scholar 

  21. Conil JM, George B, Breden A et al (2006) Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 28:226–230

    Article  CAS  PubMed  Google Scholar 

  22. Mueller EW, Boucher BA (2009) The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect (Larchmt) 10:563–570

    Article  Google Scholar 

  23. Layeux B, Taccone FS, Fagnoul D, Vincent JL, Jacobs F (2010) Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 54:4939–4941

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A (2007) Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45:753–760

    Article  CAS  PubMed  Google Scholar 

  25. Tian Q, Gomersall CD, Ip M, Tan PE, Joynt GM, Choi GY (2008) Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother 52:1009–1013

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Hafner V, Czock D, Burhenne J et al (2010) Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 54:2596–2602

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Ghannoum MA, Kuhn DM (2002) Voriconazole-better chances for patients with invasive mycoses. Eur J Med Res 7:242–256

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Intensive Care, University Hospital, Vrije Universiteit Brussel, Brussels, Belgium

    P. M. Honoré, R. Jacobs & H. D. Spapen

Authors
  1. P. M. Honoré
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. D. Spapen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. M. Honoré .

Editor information

Editors and Affiliations

  1. Université libre de Bruxelles, Dept. of Intensive Care, Erasme Hospital, Brussels, Belgium

    Jean-Louis Vincent Prof.

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Honoré, P.M., Jacobs, R., Spapen, H.D. (2015). Optimizing Antimicrobial Efficacy at Minimal Toxicity: A Novel Indication for Continuous Renal Replacement Therapy?. In: Vincent, JL. (eds) Annual Update in Intensive Care and Emergency Medicine 2015. Annual Update in Intensive Care and Emergency Medicine 2015, vol 2015. Springer, Cham. https://doi.org/10.1007/978-3-319-13761-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-13761-2_6

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-13760-5

  • Online ISBN: 978-3-319-13761-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation